NCT03119701View on ClinicalTrials.gov

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 18, 2017

Primary Completion Date

September 23, 2019

Study Completion Date

October 3, 2019

Conditions
Preventive MedicineMulti Organ Failure
Interventions
DRUG

Interferon Beta-1A

Lyophilisate for solution for injection.

DRUG

Placebo

Lyophilisate for solution for injection as placebo.

Trial Locations (9)

51014

Tartu University Hospital, Tartu

FI-00290

Helsinki University Hospital, Helsinki

FI-40620

Central Finland Central Hospital, Jyväskylä

FI-53130

South Karelia Central Hospital, Lappeenranta

FI-90220

Oulu University Hospital, Oulu

FI-33520

Tampere University Hospital, Tampere

FFI-20520

Turku University Hospital, Turku

LT-50161

Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas

LT-08661

Vilnius University Hospital Santaros klinikos, Vilnius

Sponsors
All Listed Sponsors
lead

Faron Pharmaceuticals Ltd

INDUSTRY

NCT03119701 - Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA | Biotech Hunter | Biotech Hunter